LG Life Science to export Factive technology to Japan.

Published: 2005-10-05 06:59:00

Updated: 2005-10-05 06:59:00

LG Life Science sold the Factive technology to aRigen, Japanese company. Factive is a derivative of the quinolone antibiotic drugs exclusively developed by LG Life Science.

The technology sale revealed a front payment of U$2 million including a milestone payment and a certain rate of revolving...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK